#USA #Cambridge #IgA nephropathy #XtalPi Holdings #siRNA therapeutics

XtalPi's Groundbreaking Achievement in siRNA Development

In a remarkable advancement for RNA therapeutics, XtalPi Holdings Limited has announced the nomination of its first small interfering RNA (siRNA) preclinical candidate aimed at treating immunoglobulin A nephropathy (IgAN). This milestone was achieved in a swift nine months thanks to the company's innovative Kodexia™ platform, which leverages the power of artificial intelligence (AI) and first-principles modeling to enhance drug discovery processes.

The Significance of IgA Nephropathy

IgAN is one of the most prevalent primary glomerular diseases worldwide, affecting approximately 10 million individuals. The disease is characterized by the deposition of immune complexes, which cause inflammation in the kidney’s filtering structures. If left untreated, IgAN can lead to significant renal decline and even kidney failure. Current treatment strategies typically combine kidney-protective therapies with targeted disease treatments, necessitating a balance between effective disease control and manageable treatment regimens.

XtalPi’s new siRNA candidate aims to tackle this challenging condition by utilizing the body's natural RNA interference mechanism to degrade specific messenger RNA (mRNA), inhibiting the production of disease-associated proteins. Such an approach not only presents a novel method of treatment but also offers the promise of improved patient outcomes through enhanced drug stability and potentially less frequent dosing.

Innovative Development through Kodexia™ Platform

The development of an siRNA candidate for IgAN proved to be a formidable engineering challenge. The target mRNA had limited viable sequence options, further complicated by existing clinical programs and a restrictive patent landscape. However, XtalPi's Kodexia™ platform rose to the occasion, identifying a previously unexplored active target region and optimizing both the siRNA sequence and its chemical modifications collaboratively. This integration of AI-driven analytics has resulted in a preclinical candidate distinguished by its superior potency, durability, and safety profile.

Preliminary in vitro results reveal that the candidate achieves a subnanomolar silencing potency, with a half-maximal inhibitory concentration (IC50) significantly lower than that of clinical-stage counterparts under similar conditions. Notably, in non-human primate studies, a single dose of the compound sustained suppression of target protein for several months, indicating not just an effective treatment but also long-lasting therapeutic effects. Furthermore, early toxicology results suggest a broad safety margin, reinforcing the candidate's potential as a leading therapy in this space.

Rapid Discovery Cycle and Future Aspirations

The rapid nine-month discovery cycle is indicative of Kodexia’s closed-loop architecture, which effectively combines generative AI, first-principles modeling, and automated experimentation. This framework allows XtalPi to conduct hundreds of in vitro and multiple in vivo experiments each week, feeding new data back into its models for continued optimization. Moreover, over 50% of the platform's initial designs have demonstrated enhanced in vivo activity compared to their controls, emphasizing the effectiveness of this novel approach.

Looking ahead, XtalPi plans to leverage these advanced capabilities for even more complex drug design challenges, such as dual-target siRNAs and new delivery strategies for siRNA therapeutics that transcend the liver. The nomination of its first siRNA preclinical candidate marks a significant step for XtalPi and solidifies its standing as a pioneer in the RNA therapeutic landscape.

With continued investment in research and collaboration with global partners, XtalPi is well-positioned to lead the charge in advanced RNA interference therapies, setting the stage for innovative treatment options in high-value disease targets like IgAN.

About XtalPi

Founded in 2015 by a team of physicists from the Massachusetts Institute of Technology, XtalPi Holdings Limited focuses on harnessing the power of quantum physics, AI, and robotics to revolutionize drug development. By fusing advanced computational techniques and automated systems, XtalPi delivers intelligent drug discovery solutions across various industries including pharmaceuticals, materials science, and agricultural technology.

As it advances its siRNA candidate towards clinical trials, the company looks forward to potentially transforming the treatment landscape for IgAN and beyond.